Cumberland Partners Ltd Acquires 245 Shares of Becton, Dickinson and Company (BDX)

Cumberland Partners Ltd lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,855 shares of the medical instruments supplier’s stock after acquiring an additional 245 shares during the period. Becton, Dickinson and makes up 1.5% of Cumberland Partners Ltd’s holdings, making the stock its 26th biggest holding. Cumberland Partners Ltd’s holdings in Becton, Dickinson and were worth $10,313,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of BDX. North Star Investment Management Corp. increased its position in shares of Becton, Dickinson and by 3.4% during the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after acquiring an additional 18 shares in the last quarter. Almanack Investment Partners LLC. bought a new stake in shares of Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust increased its position in shares of Becton, Dickinson and by 1.4% during the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 9 shares in the last quarter. QCI Asset Management Inc. NY increased its position in shares of Becton, Dickinson and by 9.2% during the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after acquiring an additional 60 shares in the last quarter. Finally, Financial Architects Inc increased its position in shares of Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after acquiring an additional 54 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

Becton, Dickinson and Company (BDX) opened at 203.87 on Tuesday. The firm has a 50-day moving average of $199.97 and a 200-day moving average of $190.93. The stock has a market capitalization of $46.39 billion, a PE ratio of 59.04 and a beta of 1.06. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period last year, the business earned $2.35 EPS. Becton, Dickinson and’s revenue was down 5.1% compared to the same quarter last year. Equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.43%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

Several equities research analysts have recently commented on the stock. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Cowen and Company reissued a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and set a $210.00 target price (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $195.79.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/12/cumberland-partners-ltd-acquires-245-shares-of-becton-dickinson-and-company-bdx.html.

In other news, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares of the company’s stock, valued at $19,517,294.37. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 over the last quarter. Company insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply